Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引:3
作者
Sznol, M. [1 ]
Ferrucci, P. F. [2 ]
Hogg, D. [3 ]
Atkins, M. [4 ]
Wolter, P. [5 ]
Guidoboni, M. [6 ]
Lebbe, C. [7 ]
Kirkwood, J. [8 ]
Schachter, J. [9 ]
Daniels, G. [10 ]
Hassel, J. [11 ]
Cebon, J. [12 ]
Gerritsen, W. [13 ]
Atkinson, V. [14 ,15 ]
Thomas, L. [16 ]
McCaffrey, J. [17 ]
Power, D. [18 ]
Jiang, J. [19 ]
Hodi, F. S. [20 ]
Wolchok, J. [21 ]
机构
[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA
[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy
[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada
[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy
[7] Hop St Louis, Dermatol, Paris, France
[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA
[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel
[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA
[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany
[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia
[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands
[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia
[15] Princess Alexandra Hosp, Greenslopes, Australia
[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France
[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland
[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland
[19] BMS, Oncol, Princeton, NJ USA
[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA
[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA
关键词
D O I
10.1093/annonc/mdw379.18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1123P
引用
收藏
页数:1
相关论文
共 50 条
[41]   Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040 [J].
Yau, Thomas ;
Zagonel, Vittorina ;
Santoro, Armando ;
Acosta-Rivera, Mirelis ;
Choo, Su Pin ;
Matilla, Ana ;
He, Aiwu Ruth ;
Gracian, Antonio Cubillo ;
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Eldawy, Tarek ;
Bruix, Jordi ;
Frassineti, Giovanni ;
Vaccaro, Gina M. ;
Tschaika, Marina ;
Scheffold, Christian ;
Shen, Yun ;
Neely, Jaclyn ;
Piscaglia, Fabio .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[42]   Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. [J].
Tawbi, Hussein Abdul-Hassan ;
Forsyth, Peter A. J. ;
Algazi, Alain Patrick ;
Hamid, Omid ;
Hodi, F. Stephen ;
Moschos, Stergios J. ;
Khushalani, Nikhil I. ;
Gonzalez, Rene ;
Lao, Christopher D. ;
Postow, Michael Andrew ;
Atkins, Michael B. ;
Ernstoff, Marc S. ;
Puzanov, Igor ;
Kudchadkar, Ragini Reiney ;
Thomas, Reena Parada ;
Tarhini, Ahmad A. ;
Jiang, Joel ;
Avila, Alexandre ;
Demelo, Sheena ;
Margolin, Kim Allyson .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43]   Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment [J].
Barros e Silva, Milton ;
Schmerling, Rafael ;
de Melo, Andreia Cristina ;
Azevedo, Sergio ;
Garicochea, Bernardo ;
McWhirter, Elaine ;
Smylie, Michael ;
Gifoni, Markus ;
dos Anjos, Carlos Henrique ;
Petrella, Teresa ;
Chacon, Matias ;
Greco, Martin ;
Nair, Suresh ;
Avila, Alexandre ;
Demelo, Sheena ;
Jiang, Joel ;
Ernst, Scott .
CANCER RESEARCH, 2017, 77
[44]   Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). [J].
Long, Georgina V. ;
Schadendorf, Dirk ;
Del Vecchio, Michele ;
Larkin, James ;
Atkinson, Victoria ;
Schenker, Michael ;
Pigozzo, Jacopo ;
Gogas, Helen J. ;
Dalle, Stephane ;
Meyer, Nicolas ;
Ascierto, Paolo A. ;
Sandhu, Shahneen ;
Eigentler, Thomas ;
Gutzmer, Ralf ;
Hassel, Jessica C. ;
Robert, Caroline ;
Carlino, Matteo ;
Di Giacomo, Anna Maria ;
Butler, Marcus O. ;
Munoz-Couselo, Eva ;
Brown, Michael P. ;
Rutkowski, Piotr ;
Haydon, Andrew ;
Grob, Jean-Jacques ;
Schachter, Jacob ;
Queirolo, Paola ;
Menzies, Alexander ;
Re, Sandra ;
Bas, Tuba O. ;
de Pril, Veerle ;
Tenney, Daniel ;
Tang, Hao ;
Weber, Jeffrey S. .
CANCER RESEARCH, 2021, 81 (13)
[45]   Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. [J].
El-Khoueiry, Anthony B. ;
Yau, Thomas ;
Kang, Yoon-Koo ;
Kim, Tae-You ;
Santoro, Armando ;
Sangro, Bruno ;
Melero, Ignacio ;
Kudo, Masatoshi ;
Hou Ming-Mo ;
Matilla, Ana ;
Tovoli, Francesco ;
Knox, Jennifer J. ;
He, Aiwu Ruth ;
El-Rayes, Bassel F. ;
Acosta-Rivera, Mirelis ;
Lim, Ho Yeong ;
Memaj, Arteid ;
Sama, Ashwin Reddy ;
Hsu, Chiun .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[46]   Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067 [J].
Hodi, F. Stephen ;
Chiarion-Sileni, Vanna ;
Gonzalez, Rene ;
Grob, Jean-Jacques ;
Rutkowski, Piotr ;
Lao, Christopher D. ;
Cowey, Charles Lance ;
Schadendorf, Dirk ;
Wagstaff, John ;
Dummer, Reinhard ;
Queirolo, Paola ;
Smylie, Michael ;
Butler, Marcus O. ;
Hill, Andrew Graham ;
Marquez-Rodas, Ivan ;
Ritchings, Corey ;
Sakkal, Leon A. ;
Wang, Peter ;
Wolchok, Jedd D. ;
Larkin, James .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47]   UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067) [J].
Wolchok, Jedd D. ;
Chiarion-Sileni, Vanna ;
Gonzalez, Rene ;
Rutkowski, Piotr ;
Grob, Jean-Jacques ;
Cowey, C. Lance ;
Lao, Christopher D. ;
Schadendorf, Dirk ;
Ferrucci, Pier F. ;
Smylie, Michael ;
Dummer, Reinhard ;
Hill, Andrew ;
Haanen, John ;
Maio, Michele ;
McArthur, Grant ;
Walker, Dana ;
Jiang, Joel ;
Horak, Christine ;
Larkin, James ;
Hodi, Stephen .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 :127-128
[48]   Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). [J].
Schadendorf, Dirk ;
Ascierto, Paolo Antonio ;
Haanen, John B. A. G. ;
Espinosa, Enrique ;
Demidov, Lev V. ;
Garbe, Claus ;
Lorigan, Paul ;
Gogas, Helen ;
Hoeller, Christoph ;
Guren, Tormod Kyrre ;
Rorive, Andree ;
Rutkowski, Piotr ;
Munoz-Couselo, Eva ;
Dummer, Reinhard ;
Carneiro, Ana ;
Hospers, Geke ;
Grigoryeva, Elena Borisovna ;
Bhore, Rafia ;
Nathan, Paul .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49]   Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). [J].
Khushalani, Nikhil I. ;
Kim, Youngchul ;
Gibney, Geoffrey Thomas ;
Kudchadkar, Ragini Reiney ;
Eroglu, Zeynep ;
Markowitz, Joseph ;
Czupryn, Maria P. ;
Thebeau, Melissa S. ;
McCormick, Lori ;
Richards, Allison ;
Weber, Jeffrey S. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50]   Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) [J].
Grob, J-J. ;
Schadendorf, D. ;
Wagstaff, J. ;
Marquez-Rodas, I. ;
Lebbe, C. ;
Ascierto, P. A. ;
Hodi, F. S. ;
Grossmann, K. ;
Hassel, J. C. ;
Walker, D. ;
Bhore, R. ;
Larkin, J. ;
Wolchok, J. D. .
ANNALS OF ONCOLOGY, 2017, 28